DF/HCC Senior Leaders hold pivotal positions in the Cancer Center. Individually, they provide day-to-day leadership and oversight of key areas that comprise the Center. Collectively, they bring diversity of viewpoints, disciplines and institutional perspectives to the Center as well as a unity and cohesion that has enabled the consortium to make significant progress during the project period. The structure of senior leadership and the time commitment of each leader are in direct relationship to the needs and objective of the Center and the relative complexity of responsibility. In addition to the Director and Deputy Director, there are ten Associate Directors who are charged with overseeing key areas of responsibility. There are also members of Senior Leadership who serve as faculty representatives to DF/HCC on behalf of their institution. This means that they are responsible for voicing the needs and perspectives of their institution on Center matters.

Public Health Relevance

Senior Leaders hold pivotal positions in the Center. They provide day-to-day leadership and oversight of key areas that comprise the Center. Collectively, they bring diversity of viewpoints, disciplines and institutional perspectives to the Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-49
Application #
8601518
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
49
Fiscal Year
2014
Total Cost
$400,840
Indirect Cost
$60,776
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Chen, Yi-Bin; Batchelor, Tracy; Li, Shuli et al. (2015) Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer 121:226-33
Waldron, Levi; Haibe-Kains, Benjamin; Culhane, Aedín C et al. (2014) Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst 106:
Yilmazel, Bahar; Hu, Yanhui; Sigoillot, Frederic et al. (2014) Online GESS: prediction of miRNA-like off-target effects in large-scale RNAi screen data by seed region analysis. BMC Bioinformatics 15:192
Mazzola, Emanuele; Chipman, Jonathan; Cheng, Su-Chun et al. (2014) Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiol Biomarkers Prev 23:1689-95
Zhao, Sihai Dave; Parmigiani, Giovanni; Huttenhower, Curtis et al. (2014) Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics 30:3062-9
Parkhitko, Andrey A; Priolo, Carmen; Coloff, Jonathan L et al. (2014) Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide. Mol Cancer Res 12:48-57
Cheng, Long; Desai, Jigar; Miranda, Carlos J et al. (2014) Human CFEOM1 mutations attenuate KIF21A autoinhibition and cause oculomotor axon stalling. Neuron 82:334-49
Akbay, Esra A; Moslehi, Javid; Christensen, Camilla L et al. (2014) D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 28:479-90
Brunner, Andrew M; Blonquist, Traci M; Sadrzadeh, Hossein et al. (2014) Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk Res 38:773-80
Karamichos, D; Hutcheon, A E K; Rich, C B et al. (2014) In vitro model suggests oxidative stress involved in keratoconus disease. Sci Rep 4:4608

Showing the most recent 10 out of 177 publications